Visiomed Group SA
PAR:ALVMG
Intrinsic Value
Visiomed Group SA engages in the development and distribution of healthcare products and services. [ Read More ]
The intrinsic value of one ALVMG stock under the Base Case scenario is 0.4799 EUR. Compared to the current market price of 0.2065 EUR, Visiomed Group SA is Undervalued by 57%.
Valuation Backtest
Visiomed Group SA
Run backtest to discover the historical profit from buying and selling ALVMG stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Visiomed Group SA
Current Assets | 6.2m |
Cash & Short-Term Investments | 2.2m |
Receivables | 4m |
Non-Current Assets | 29.1m |
Long-Term Investments | 1.2m |
PP&E | 8.7m |
Intangibles | 19.3m |
Other Non-Current Assets | 1k |
Current Liabilities | 3.7m |
Accounts Payable | 2.4m |
Accrued Liabilities | 981k |
Other Current Liabilities | 250k |
Non-Current Liabilities | 8.9m |
Long-Term Debt | 8.2m |
Other Non-Current Liabilities | 699k |
Earnings Waterfall
Visiomed Group SA
Revenue
|
12m
EUR
|
Cost of Revenue
|
-1m
EUR
|
Gross Profit
|
11m
EUR
|
Operating Expenses
|
-14m
EUR
|
Operating Income
|
-3m
EUR
|
Other Expenses
|
-515k
EUR
|
Net Income
|
-3.5m
EUR
|
Free Cash Flow Analysis
Visiomed Group SA
ALVMG Profitability Score
Profitability Due Diligence
Visiomed Group SA's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Visiomed Group SA's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
ALVMG Solvency Score
Solvency Due Diligence
Visiomed Group SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Visiomed Group SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALVMG Price Targets Summary
Visiomed Group SA
According to Wall Street analysts, the average 1-year price target for ALVMG is 0.714 EUR with a low forecast of 0.707 EUR and a high forecast of 0.735 EUR.
Shareholder Return
ALVMG Price
Visiomed Group SA
Average Annual Return | 46.16% |
Standard Deviation of Annual Returns | 189.81% |
Max Drawdown | -96% |
Market Capitalization | 60.8m EUR |
Shares Outstanding | 294 056 992 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Visiomed Group SA engages in the development and distribution of healthcare products and services. The company is headquartered in Puteaux, Ile-De-France. The company went IPO on 2011-07-05. The firm is primarily engaged in the design, manufacture and marketing of medical electronics. The company develops and markets health products in the fields of medical and well-being self-diagnosis to provide non-drug prevention and treatment solutions. The firm's product portfolio comprises MyThermo, an infrared contact-less medical thermometer; MyTension, an automatic blood pressure and pulse monitors; MyOxy, a finger pulse oximeter; MyECG, a pocket electrodiogram; MyGluco, a blood sugar meter; My Coach, a health and fitness coach, and Epiderm, a telemedicine dermatology mobile application, among others. The firm serves pharmacies, health professionals, hospitals, clinics and retirement homes. The company also offers connected solutions and COVID devices such as deconfinement kits, masks, filter cushion, serological tests etc. The Company’s subsidiaries include ThermoFlash and BewellConnect.
Contact
IPO
Employees
Officers
The intrinsic value of one ALVMG stock under the Base Case scenario is 0.4799 EUR.
Compared to the current market price of 0.2065 EUR, Visiomed Group SA is Undervalued by 57%.